Citations

Clear

6274 citation(s) found for "To, Andrew".

Traf2 and NCK Interacting Kinase Is a Critical Regulator of Procollagen I Trafficking and Hepatic Fibrogenesis in Mice
Buchl, Samuel C. , Hanquier, Zachary , Haak, Andrew J. , Thomason, Yvonne M. , Huebert, Robert C. , Shah, Vijay H. , Maiers, Jessica L. , Huebert, Robert

Mayo Clinic

Hepatology Communications | October 22, 2021 | Volume: 6 | Issue: 3 | Pages: 593-609

10.1002/hep4.1835 | PMID 34677004 Get It

Hepatic fibrosis is driven by deposition of matrix proteins following liver injury. Hepatic stellate cells (HSCs) drive fibrogenesis, producing matrix proteins, including procollagen I, which matures into collagen I following secretion. Disrupting intracellular procollagen processing and trafficking causes endoplasmic reticulum stress and stress‐induced HSC apoptosis and thus is an attractive antifibrotic strategy. We designed an immunofluorescence‐based small interfering RNA (siRNA) screen to identify procollagen I trafficking regulators, hypothesizing that these proteins could serve as antifibrotic targets. A targeted siRNA screen was performed using immunofluorescence to detect changes in intracellular procollagen I. Tumor necrosis factor receptor associated factor 2 and noncatalytic region of tyrosine kinase‐interacting kinase (TNIK) was identified and interrogated in vitro and in vivo using the TNIK kinase inhibitor NCB‐0846 or RNA interference‐mediated knockdown. Our siRNA screen identified nine genes whose knockdown promoted procollagen I retention, including the serine/threonine kinase TNIK. Genetic deletion or pharmacologic inhibition of TNIK through the small molecule inhibitor NCB‐0846 disrupted procollagen I trafficking and secretion without impacting procollagen I expression. To investigate the role of TNIK in liver fibrogenesis, we analyzed human and murine livers, finding elevated TNIK expression in human cirrhotic livers and increased TNIK expression and kinase activity in both fibrotic mouse livers and activated primary human HSCs. Finally, we tested whether inhibition of TNIK kinase activity could limit fibrogenesis in vivo. Mice receiving NCB‐0846 displayed reduced CCl4‐induced fibrogenesis compared to CCl4 alone, although α‐smooth muscle actin levels were unaltered. Conclusions: Our siRNA screen effectively identified TNIK as a key kinase involved in procollagen I trafficking in vitro and hepatic fibrogenesis in vivo.
A Coronavirus Disease 2019 Pandemic Pivot: Development of the American Board of Anesthesiology’s Virtual APPLIED Examination
Keegan, Mark T. , McLoughlin, Thomas M, Fiadjoe, John E. , Pisacano, Margaret M., Harman, Ann E., Patterson, Andrew J., Warner, David O. , Sun, Huaping

Mayo Clinic

Anesthesia & Analgesia | October 21, 2021 | Volume: 133 | Issue: 5 | Pages: 1331-1341

10.1213/ane.0000000000005750 | PMID 34517394 Get It

In 2020, the coronavirus disease 2019 (COVID-19) pandemic interrupted the administration of the APPLIED Examination, the final part of the American Board of Anesthesiology (ABA) staged examination system for initial certification. In response, the ABA developed, piloted, and implemented an Internet-based “virtual” form of the examination to allow administration of both components of the APPLIED Exam (Standardized Oral Examination and Objective Structured Clinical Examination) when it was impractical and unsafe for candidates and examiners to travel and have in-person interactions. This article describes the development of the ABA virtual APPLIED Examination, including its rationale, examination format, technology infrastructure, candidate communication, and examiner training. Although the logistics are formidable, we report a methodology for successfully introducing a large-scale, high-stakes, 2-element, remote examination that replicates previously validated assessments.
Depression and anxiety screening in emergency department patients with recurrent abdominal pain: An evidence synthesis for a clinical practice guideline
Silva, Lucas Oliveira J. e , Prakken, Steven, Meltzer, Andrew C. , Broder, Joshua , Gerberi, Dana , Upadhye, Suneel , Carpenter, Christopher R. , Bellolio, Fernanda , Oliveira J E Silva, Lucas , Broder, Joshua S , Bellolio, M Fernanda , Carpenter, Christopher R , Meltzer, Andrew C

Mayo Clinic

Academic Emergency Medicine | October 21, 2021 | Volume: 29 | Issue: 5 | Pages: 615-629

10.1111/acem.14394 | PMID 34665903 Get It

AbstractBackgroundRecurrent abdominal pain in the emergency department (ED) might represent an opportunity for screening of depression and/or anxiety.MethodsWe systematically searched five databases for studies evaluating the effect of screening for depression and/or anxiety in ED patients with recurrent and undifferentiated abdominal pain. Given paucity of direct evidence, we also searched for indirect evidence including studies that assessed prevalence of depression and/or anxiety in EDs (not necessarily recurrent abdominal pain), diagnostic accuracy of screening tools, effectiveness of screening in other settings, and outcomes such as repeat ED visits of patients with abdominal pain who were screened in the ED. Two methodologists evaluated certainty in the evidence using the GRADE approach.ResultsA total of 4,337 citations were reviewed, and zero studies were found on the effect of screening in patients with recurrent and undifferentiated abdominal pain in the ED. A total of 35 studies were included as relevant indirect evidence. In studies of ED patients with abdominal pain, depression ranged from 10% to 29%, while anxiety ranged from 18% to 50%. False positives appear to be an issue given relatively low specificity of screening tools. One randomized trial including ED patients with vague symptoms evaluated the effect of depression screening on a composite outcome of depression recognition, psychiatric consultation, or referral by the emergency physician (risk ratio = 1.49, 95% confidence interval [CI] = 0.49 to 4.53, very low certainty). One study reported that patients with undifferentiated abdominal pain who screened positive for depression have had increased ED recidivism (odds ratio = 3.17, 95% CI = 1.14 to 8.85, very low certainty).ConclusionsWe were unable to identify any evidence that confirms that depression or anxiety screening in ED patients with recurrent and undifferentiated abdominal pain improves outcomes or changes management downstream.
Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
Castellino, Alessia , Wang, Yucai , Maurer, Matthew J. , Link, Brian K. , Farooq, Umar , Feldman, Andrew L. , Syrbu, Sergei , Inwards, David J. , Ansell, Stephen M. , Allmer, Cristine, Cohen, Jonathon B. , Martin, Peter , Nowakowski, Grzegorz S. , Maurer, Matthew , Link, Brian K , Feldman, Andrew L , Paludo, Jonas , Witzig, T.E. , Cohen, Jonathon B , Cerhan, James R , Farooq, Umar , Wang, Yucai , Syrbu, Sergei , Larson, Melissa C. , Habermann, Thomas M. , Paludo, Jonas , Witzig, Thomas E. , Slager, Susan L. , Cerhan, James R.

Mayo Clinic

Blood Advances | October 20, 2021 | Volume: 6 | Issue: 4 | Pages: 1350-1360

10.1182/bloodadvances.2021005715 | PMID 34662895 Get It

AbstractBecause there have been a dvances in frontline treatment for mantle cell lymphoma (MCL) over the last 2 decades, we sought to characterize the changes in frontline treatment patterns and their association with outcomes. Patients with newly diagnosed MCL from September 2002 through June 2015 were enrolled in a prospective cohort study, and clinical characteristics, treatment, and clinical outcomes were compared between patients diagnosed from 2002 to 2009 (Era 1) compared with 2010 to 2015 (Era 2). Patient age, sex, and simplified MCL International Prognostic Index (sMIPI) score were similar between the 2 groups. In patients age 65 years or younger, there was less use of rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (R-Hyper-CVAD) (16.1% vs 8.8%) but more use of rituximab plus maximum-strength cyclophosphamide, doxorubicin, vincristine, and prednisone (R-maxi-CHOP) alternating with rituximab plus high-dose cytarabine (R-HiDAC), also known as the Nordic regimen, and R-CHOP alternating with rituximab plus dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) (1.1% vs 26.4%) and less use of R-CHOP or R-CHOP-like regimens (64.5% vs 35.2%) but more use of R-bendamustine (0% vs 12.1%) in Era 2 (P < .001). These changes were associated with improved event-free survival (EFS; 5-year EFS, 34.3% vs 50.0%; P = .010) and overall survival (OS; 5-year OS, 68.8% vs 81.6%; P = .017) in Era 2. In patients older than age 65 years, there was less use of R-CHOP or R-CHOP-like therapy (39.0% vs 14.3%) and nonstandard systemic therapy (36.6% vs 13.0%) but more use of R-bendamustine (0% vs 49.4%). These changes were associated with a trend for improved EFS (5-year EFS, 25.4% vs 37.5%; P = .051) in Era 2. The shift from R-CHOP or R-CHOP-like regimens to R-bendamustine was associated with improved EFS (5-year EFS, 25.0% vs 44.6%; P = .008) in Era 2. Results from this prospective cohort study provide critical real-world evidence for improved outcomes with evolving frontline patterns of care in patients with MCL.
The Kidney in Normal Aging
Đenić, Aleksandar , Glassock, Richard J. , Rule, Andrew D. , Rule, Andrew D , Denic, Aleksandar

Mayo Clinic

Clinical Journal of the American Society of Nephrology | October 20, 2021 | Volume: 17 | Issue: 1 | Pages: 137-139

10.2215/cjn.10580821 | PMID 34670799 Get It

Sorbitol Is a Severity Biomarker for PMM2‐CDG with Therapeutic Implications
Ligezka, Anna N. , Radenkovic, Silvia , Saraswat, Mayank , Garapati, Kishore , Ranatunga, Wasantha , Yanaihara, Hitoshi, Preston, Graeme , Brucker, William , McGovern, Renee M., Cassiman, David , Johnsen, Christin , Lam, Christina , Edmondson, Andrew C. , Raymond, Kimiyo , Oglesbee, Devin , Pandey, Akhilesh , Reid, Joel M. , Muthusamy, Karthik , Morava, Eva , Pandey, Akhilesh , Oglesbee, Devin , Edmondson, Andrew C , Garapati, Kishore , Krzyściak, Wirginia , Muthusamy, Karthik , Mercimek‐Andrews, Saadet , Larson, Austin , Ghesquière, Bart , Witters, Peter , Perlstein, Ethan , Kozicz, Tamás , Morava, Éva

Mayo Clinic

Annals of Neurology | October 20, 2021 | Volume: 90 | Issue: 6 | Pages: 887-900

10.1002/ana.26245 | PMID 34652821 Get It

ObjectiveEpalrestat, an aldose reductase inhibitor increases phosphomannomutase (PMM) enzyme activity in a PMM2‐congenital disorders of glycosylation (CDG) worm model. Epalrestat also decreases sorbitol level in diabetic neuropathy. We evaluated the genetic, biochemical, and clinical characteristics, including the Nijmegen Progression CDG Rating Scale (NPCRS), urine polyol levels and fibroblast glycoproteomics in patients with PMM2‐CDG.MethodsWe performed PMM enzyme measurements, multiplexed proteomics, and glycoproteomics in PMM2‐deficient fibroblasts before and after epalrestat treatment. Safety and efficacy of 0.8 mg/kg/day oral epalrestat were studied in a child with PMM2‐CDG for 12 months.ResultsPMM enzyme activity increased post‐epalrestat treatment. Compared with controls, 24% of glycopeptides had reduced abundance in PMM2‐deficient fibroblasts, 46% of which improved upon treatment. Total protein N‐glycosylation improved upon epalrestat treatment bringing overall glycosylation toward the control fibroblasts’ glycosylation profile. Sorbitol levels were increased in the urine of 74% of patients with PMM2‐CDG and correlated with the presence of peripheral neuropathy, and CDG severity rating scale. In the child with PMM2‐CDG on epalrestat treatment, ataxia scores improved together with significant growth improvement. Urinary sorbitol levels nearly normalized in 3 months and blood transferrin glycosylation normalized in 6 months.InterpretationEpalrestat improved PMM enzyme activity, N‐glycosylation, and glycosylation biomarkers in vitro. Leveraging cellular glycoproteome assessment, we provided a systems‐level view of treatment efficacy and discovered potential novel biosignatures of therapy response. Epalrestat was well‐tolerated and led to significant clinical improvements in the first pediatric patient with PMM2‐CDG treated with epalrestat. We also propose urinary sorbitol as a novel biomarker for disease severity and treatment response in future clinical trials in PMM2‐CDG. ANN NEUROL 20219999:n/a–n/a
Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
Tosun, Duygu , Demir, Zeynep , Aisen, Paul, Jack, Clifford R. , Jagust, William, Petersen, Ronald C. , Saykin, Andrew J. , Shaw, Leslie M. , Trojanowski, John Q. , Weiner, Michael W. , Initiative, for the Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Tosun, Duygu , Veitch, Dallas P. , Weintraub, Daniel , Initiative, for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | October 19, 2021 | Volume: 18 | Issue: 7 | Pages: 1370-1382

10.1002/alz.12480 | PMID 34647694 Get It

Abstract Introduction Amyloid beta (Aβ), tau, and neurodegeneration jointly with the Alzheimer's disease (AD) risk factors affect the severity of clinical symptoms and disease progression. Methods Within 248 Aβ‐positive elderly with and without cognitive impairment and dementia, partial least squares structural equation pathway modeling was used to assess the direct and indirect effects of imaging biomarkers (global Aβ‐positron emission tomography [PET] uptake, regional tau‐PET uptake, and regional magnetic resonance imaging–based atrophy) and risk‐factors (age, sex, education, apolipoprotein E [ APOE ], and white‐matter lesions) on cross‐sectional cognitive impairment and longitudinal cognitive decline. Results Sixteen percent of variance in cross‐sectional cognitive impairment was accounted for by Aβ, 46% to 47% by tau, and 25% to 29% by atrophy, although 53% to 58% of total variance in cognitive impairment was explained by incorporating mediated and direct effects of AD risk factors. The Aβ–tau–atrophy pathway accounted for 50% to 56% of variance in longitudinal cognitive decline while Aβ, tau, and atrophy independently explained 16%, 46% to 47%, and 25% to 29% of the variance, respectively. Discussion These findings emphasize that treatments that remove Aβ and completely stop downstream effects on tau and neurodegeneration would only be partially effective in slowing of cognitive decline or reversing cognitive impairment.
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Kwan, Tanya T. , Tinker, Anna V. , Oaknin, Ana , Aghajanian, Carol , Lorusso, Domenica , Colombo, Nicoletta , Dean, Andrew , Weberpals, Johanne I. , Severson, Eric A. , Vo, Lan-Thanh, Goble, Sandra, Maloney, Lara , Harding, Thomas , McNeish, Iain A. , Lin, Kevin K. , Swisher, Elizabeth M. , McNeish, Iain A , Swisher, Elizabeth M , Oza, Amit M. , Ray-Coquard, Isabelle L. , Kaufmann, Scott H. , Ledermann, Jonathan A. , Coleman, Robert L.

Mayo Clinic

JAMA Oncology | October 18, 2021 | Volume: 7 | Issue: 12 | Pages: 1772

10.1001/jamaoncol.2021.4664 | PMID 34647981 Get It

Treatment of Women After Bilateral Salpingo-oophorectomy Performed Prior to Natural Menopause
Kaunitz, Andrew M., Kapoor, Ekta , Faubion, Stephanie, Faubion, Stephanie S.

Mayo Clinic

JAMA | October 13, 2021 | Volume: 326 | Issue: 14 | Pages: 1429

10.1001/jama.2021.3305 | PMID 34636868 Get It

Autoimmune Encephalitis After SARS-CoV-2 Infection
Sánchez, Cristina Valencia, Theel, Elitza S. , Binnicker, Matthew J. , Toledano, Michel , Valencia Sanchez, Cristina, Theel, Elitza, Binnicker, Matthew, McKeon, Andrew

Mayo Clinic

Neurology | October 11, 2021 | Volume: 97 | Issue: 23 | Pages: No page available

10.1212/wnl.0000000000012931 | PMID 34635560 Get It